•  
  •  
 

Lynchburg Journal of Medical Science

Specialty

Dermatology

Advisor

James Shuler, DMSc, PA-C

Abstract

Grover’s disease, also known as transient acantholytic dermatosis, is an uncommon dermatologic condition characterized by pruritic papulovesicular eruptions that predominantly affect the trunk of older adults. Although the disease is often self-limited, it may significantly impair quality of life. This review summarizes treatment options and emerging therapies for Grover’s disease reported in the literature since 2019. A comprehensive search of PubMed and MEDLINE identified 1,068 records, of which thirteen publications met inclusion criteria, including one systematic review, one narrative review, one nonrandomized controlled study, nine case reports, and one fact sheet, representing a total of 337 patients. The literature demonstrates the absence of a standardized treatment approach; however, several therapeutic classes show clinical benefit. First-line therapies commonly include topical corticosteroids, emollients, topical vitamin D analogs, and antihistamines, while second-line options include oral retinoids, systemic corticosteroids, phototherapy, and antibiotics, particularly tetracyclines. Emerging therapies, including biologic agents such as etanercept and dupilumab, have shown potential benefit in patients with severe or treatment-refractory disease. Overall, management of Grover’s disease remains largely symptom-directed. Additional research is needed to further understand disease mechanisms and to establish evidence-based treatment guidelines.

Download

Share

COinS